BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26078298)

  • 21. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
    Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
    Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
    Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
    Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
    Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
    Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
    Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
    J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble CD146 as a Potential Target for Preventing Triple Negative Breast Cancer MDA-MB-231 Cell Growth and Dissemination.
    Sharma A; Joshkon A; Ladjimi A; Traboulsi W; Bachelier R; Robert S; Foucault-Bertaud A; Leroyer AS; Bardin N; Somasundaram I; Blot-Chabaud M
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055160
    [No Abstract]   [Full Text] [Related]  

  • 31. miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer.
    Kong P; Chen L; Yu M; Tao J; Liu J; Wang Y; Pan H; Zhou W; Wang S
    Cell Death Dis; 2018 Oct; 9(11):1059. PubMed ID: 30333478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
    Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
    Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
    Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
    Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells.
    Kwon YJ; Leibovitch BA; Bansal N; Pereira L; Chung CY; Ariztia EV; Zelent A; Farias EF; Waxman S
    Oncotarget; 2017 Oct; 8(51):88421-88436. PubMed ID: 29179446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.
    Li T; Zhang Q; Zhang J; Yang G; Shao Z; Luo J; Fan M; Ni C; Wu Z; Hu X
    BMC Cancer; 2014 Feb; 14():96. PubMed ID: 24529079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death.
    Rowland LK; Campbell PS; Mavingire N; Wooten JV; McLean L; Zylstra D; Thorne G; Daly D; Boyle K; Whang S; Unternaehrer J; Brantley EJ
    J Cell Biochem; 2019 Apr; 120(4):6004-6014. PubMed ID: 30450577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.